On June 1, 2026, Oak Hill Bio, a clinical-stage rare disease therapeutics company, announced the closing of a $32.5 million Series A financing. The round was co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors, with participation from KCap Biotechnology Fund. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on patent matters related to the transaction.

Proceeds from the financing will be used to advance rugonersen, an investigational ASO therapy for the treatment of Angelman syndrome, into a pivotal Phase 3 clinical study. Angelman syndrome is a devastating neurodevelopmental disorder affecting approximately 30,000 diagnosed patients in the U.S. and EU5 with no approved treatments. Rugonersen was originally developed by Roche as a highly potent and specific therapy to restore UBE3A production in neurons.

The Wilson Sonsini team that advised Oak Hill Bio on the patent matters related to the transaction includes Laurie McNamara, Sean Reed, and Khailee Marischuk.

For more information, please see Oak Hill Bio’s news release.